Research Analysts Issue Forecasts for ORKA FY2024 Earnings

Oruka Therapeutics, Inc. (NASDAQ:ORKA) – HC Wainwright decreased their FY2024 EPS estimates for Oruka Therapeutics in a report issued on Monday, November 25th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings per share of ($2.24) for the year, down from their prior forecast of ($1.56). HC Wainwright has a “Buy” rating and a $45.00 price objective on the stock. The consensus estimate for Oruka Therapeutics’ current full-year earnings is ($3.10) per share. HC Wainwright also issued estimates for Oruka Therapeutics’ Q4 2024 earnings at ($0.39) EPS, Q3 2025 earnings at ($0.52) EPS and FY2025 earnings at ($1.98) EPS.

ORKA has been the subject of a number of other reports. Jefferies Financial Group started coverage on Oruka Therapeutics in a research note on Friday, September 13th. They issued a “buy” rating and a $40.00 target price for the company. TD Cowen started coverage on Oruka Therapeutics in a research report on Monday, September 16th. They set a “buy” rating for the company. Leerink Partnrs raised Oruka Therapeutics to a “strong-buy” rating in a research note on Tuesday, September 17th. Lifesci Capital began coverage on shares of Oruka Therapeutics in a report on Monday, September 16th. They issued an “outperform” rating and a $41.00 price objective for the company. Finally, Stifel Nicolaus began coverage on Oruka Therapeutics in a report on Friday, October 11th. They set a “buy” rating and a $49.00 target price on the stock. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Oruka Therapeutics presently has an average rating of “Buy” and a consensus target price of $43.17.

Oruka Therapeutics Stock Performance

Shares of ORKA opened at $18.69 on Wednesday. The firm has a 50 day simple moving average of $25.86. The firm has a market cap of $654.15 million, a price-to-earnings ratio of -2.98 and a beta of 0.87. Oruka Therapeutics has a 52-week low of $18.20 and a 52-week high of $53.88.

Institutional Investors Weigh In On Oruka Therapeutics

Several hedge funds have recently made changes to their positions in the stock. The Manufacturers Life Insurance Company acquired a new position in shares of Oruka Therapeutics in the 3rd quarter valued at $1,037,000. FMR LLC acquired a new position in shares of Oruka Therapeutics in the 3rd quarter worth approximately $114,763,000. Great Point Partners LLC acquired a new stake in Oruka Therapeutics during the 3rd quarter valued at $12,614,000. Braidwell LP acquired a new position in Oruka Therapeutics in the third quarter worth $12,640,000. Finally, Janus Henderson Group PLC bought a new stake in shares of Oruka Therapeutics during the third quarter worth $5,840,000. Institutional investors own 56.44% of the company’s stock.

Oruka Therapeutics Company Profile

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.